GS Paper III · Science & Technology · Biotechnology
🎯 Monoclonal Antibodies — Precision Weapons Against Disease
What is a mAb · Y-Shaped Structure · How They Work · Production (Hybridoma) · Naming Convention · Cancer · COVID-19 · Nipah Virus (m102.4) · NexCAR19 India · CAR-T · Diagnostic & Research Uses · Nobel 1984 · UPSC PYQ 2025 & MCQs
🎯
What is a Monoclonal Antibody? — The "Guided Missile" of Medicine
Core Concept · Nobel 1984 · Non-Bio Friendly
📖 Definition
A Monoclonal Antibody (mAb) is a laboratory-made protein that precisely targets one specific antigen (a foreign substance or disease-causing molecule). It is designed to mimic the immune system's natural antibodies — but with extreme specificity: all molecules of a given mAb are identical clones targeting the same single target. "Mono" = one · "Clonal" = all identical copies.
🎯 Super Simple Analogy — For Non-Biology Students
Think of disease-causing proteins as criminals in a city. Your immune system sends police (natural antibodies) — but they arrest many different criminals with varying success. A monoclonal antibody is like a specially trained sniper programmed to neutralise ONLY one specific criminal (one specific antigen) — with pinpoint accuracy, leaving everything else untouched. This precision is what makes mAbs revolutionary.
🔍 Natural Antibody vs Monoclonal Antibody
Structure of an antibody (IgG): The Y-shaped protein has two Fab regions (antigen-binding arms at the top) and one Fc region (stem — determines immune effector function). In a mAb, both Fab arms are identical and target the same epitope. (Source: Wikimedia Commons)
🔑 Key Structural Parts
Fab region — Fragment antigen-binding. The two "arms" of the Y — binds specifically to the antigen (target).
Fc region — Fragment crystallisable. The "stem" — triggers immune effector functions (complement activation, ADCC).
Variable region — Unique tip of each Fab arm — determines which antigen the antibody recognises. In mAbs, this is engineered for one specific target.
Constant region — Rest of the antibody — determines antibody class (IgG, IgM etc.)
Fc region — Fragment crystallisable. The "stem" — triggers immune effector functions (complement activation, ADCC).
Variable region — Unique tip of each Fab arm — determines which antigen the antibody recognises. In mAbs, this is engineered for one specific target.
Constant region — Rest of the antibody — determines antibody class (IgG, IgM etc.)
🏅 Nobel Prize — 1984
Niels K. Jerne, Georges J.F. Köhler & César Milstein awarded the Nobel Prize in Physiology or Medicine 1984 for developing the hybridoma technique to produce mAbs. Köhler & Milstein published the landmark paper in 1975 — one of the most cited papers in science history.
🧠 Quick Memory Aid
mAb = "Lock & Key" taken to the extreme. Every lock (antigen) has one key (mAb). The mAb key is manufactured in billions of identical copies — all fitting only that one lock. This is why mAbs can be used as both treatments (blocking the lock) and diagnostic tools (detecting when the lock exists in a patient sample).
⚙
How Do Monoclonal Antibodies Work? High Yield
Mechanisms · 4 Ways mAbs Fight Disease
📌 Core Principle
A monoclonal antibody is engineered to bind to a specific antigen (usually a surface protein on a cancer cell, virus, or immune cell). Once bound, it can work in several ways to eliminate or neutralise the threat — depending on how it is designed.
🚫
① Direct Blocking (Neutralisation)
The mAb binds to the antigen and physically blocks its function — like plugging a lock so nothing else can fit. Example: COVID-19 mAbs (casirivimab + imdevimab) bind the spike protein of SARS-CoV-2, preventing it from attaching to ACE2 receptors on human cells → virus cannot enter cells → infection stopped.
🔔
② Flagging for Immune Destruction (ADCC)
mAb binds to cancer cell surface → the Fc region acts as a "flag" → signals Natural Killer (NK) cells and macrophages to attack and destroy the flagged cell. Called Antibody-Dependent Cell-mediated Cytotoxicity (ADCC). Example: Rituximab in B-cell lymphoma.
☠
③ Drug Delivery (ADC — Trojan Horse)
The mAb is linked to a toxic drug or radioactive substance. It navigates to the cancer cell, binds specifically, then releases the toxin inside — killing that cell without harming normal cells. Called Antibody-Drug Conjugate (ADC). Example: Kadcyla (T-DM1) in HER2+ breast cancer.
🛡
④ Checkpoint Blockade (Immunotherapy)
Cancers hide from the immune system by activating "checkpoint" proteins (PD-1/PD-L1) that suppress T-cells. mAbs like Pembrolizumab (Keytruda) block these checkpoints → T-cells are unleashed → they recognize and kill cancer cells. Called Immune Checkpoint Inhibitors (ICI).
🎯 mAb Mechanisms at a Glance
🦠 COVID-19 Example — How mAbs Worked Against SARS-CoV-2
The SARS-CoV-2 virus uses its spike protein to attach to the ACE2 receptor on human lung cells — like a key fitting a lock. COVID-19 monoclonal antibodies (e.g., Casirivimab + Imdevimab — Roche's REGEN-COV, available in India) were engineered to bind to different sites on the spike protein, physically blocking it from fitting the ACE2 "lock". Result: virus could not enter cells → reduced hospitalisation by ~85% in high-risk patients. However, with new variants like Omicron, many mAbs lost efficacy because the spike protein mutated — highlighting a key limitation of mAbs.
🏭
How Monoclonal Antibodies Are Produced — The Hybridoma Technique
Köhler & Milstein 1975 · Nobel 1984 · Fully Human mAbs
🧬 The Core Problem Solved
The body's B-cells naturally make antibodies — but each B-cell lives only a short time. Scientists needed a way to produce one specific antibody indefinitely and in large quantities. The solution: fuse a short-lived antibody-producing B-cell with a long-lived (immortal) myeloma (cancer) cell → creating a hybridoma — a cell that is both immortal AND produces one specific antibody forever.
🔬 Hybridoma Method — Step by Step
🐭
① Immunise Mouse
Inject antigen (target protein) into mouse → mouse immune system produces B-cells making antibodies against it
🧫
② Isolate B-cells
Harvest spleen cells (rich in B-cells). Each B-cell makes one specific antibody but dies quickly in culture
⚗
③ Fuse with Myeloma
Fuse B-cells with myeloma (cancer) cells → creates hybridomas — immortal cells that produce specific antibodies
🔍
④ Select & Screen
Each hybridoma tested to find the one producing the exact antibody needed. Unwanted hybrids discarded
🏭
⑤ Mass Produce
Winning hybridoma grown in bioreactors → produces unlimited identical mAb molecules for therapeutic or diagnostic use
Hybridoma method for monoclonal antibody production: Mouse immunised → B-cells fused with myeloma cells → hybridoma selected → mAb produced in large quantities. (Source: Wikimedia Commons)
🏷 Naming Convention — How to Read a mAb Name (UPSC Trick!)
WHO standard naming: [prefix] + [target substem] + [source substem] + "mab"
PREFIX
PEMBRO-
Unique identifier (random)
TARGET
-LI-
Immunomodulatory (immune system)
SOURCE
-ZU-
Humanised (from mouse, made human)
SUFFIX
-MAB
Monoclonal antibody
So PEMBROLIZUMAB = Immune-targeting + humanised + mAb = Keytruda (PD-1 checkpoint inhibitor for cancer)
-umab — Fully Human
-zumab — Humanised (from mouse)
-ximab — Chimeric (part mouse, part human)
-omab — Mouse (murine) origin
| Example mAb | Type | Target | Used For |
|---|---|---|---|
| Rituximab (-ximab) | Chimeric | CD20 on B-cells | B-cell lymphoma, rheumatoid arthritis |
| Trastuzumab (-zumab) | Humanised | HER2 receptor | HER2+ breast & gastric cancer |
| Adalimumab (-umab) | Fully human | TNF-α (inflammation) | Rheumatoid arthritis, Crohn's disease |
| Pembrolizumab (-zumab) | Humanised | PD-1 checkpoint | Multiple cancers (Keytruda) |
| Bevacizumab (-zumab) | Humanised | VEGF (blood vessel growth) | Colorectal, lung, brain cancers |
| Casirivimab (-umab) | Fully human | SARS-CoV-2 spike protein | COVID-19 treatment |
| m102.4 | Fully human | Nipah/Hendra G glycoprotein | Nipah virus (compassionate use) |
💊
Applications of Monoclonal Antibodies — Therapeutics to Diagnostics
Cancer · Autoimmune · Infectious Disease · ELISA · m102.4
🎗
Cancer Treatment
The largest application. mAbs target cancer-specific proteins (HER2, CD20, VEGF, PD-1). Examples: Herceptin (breast cancer), Keytruda (melanoma, lung, cervical), Avastin (colorectal). Used as monotherapy or combined with chemo.
🔴
Autoimmune Diseases
Block pro-inflammatory cytokines (TNF-α, IL-6, IL-17). Examples: Adalimumab/Humira (rheumatoid arthritis, psoriasis — world's best-selling drug for over a decade), Tocilizumab (COVID-19 cytokine storm, RA), Dupilumab (eczema, asthma).
🦠
Infectious Diseases
COVID-19: Casirivimab + Imdevimab (REGEN-COV). Nipah: m102.4. Ebola: Inmazeb (atoltivimab + maftivimab + odesivimab — FDA approved 2020). HIV: broadly neutralising antibodies (bNAbs) in trials.
🧪
Diagnostic Tools (ELISA)
mAbs are the foundation of ELISA (Enzyme-Linked Immunosorbent Assay) — used to detect HIV, hepatitis, COVID-19 antigens, pregnancy (hCG detection), food allergens, and drugs in blood. Rapid antigen tests for COVID-19 use mAbs.
🔬
Research Tools
In laboratories, mAbs are used to identify, locate, and study specific proteins in cells (Western blot, immunofluorescence, flow cytometry). Essential tools in cell biology, immunology, and drug discovery — the backbone of modern biomedical research.
💊
Drug Delivery (ADC)
Antibody-Drug Conjugates (ADCs) — mAb linked to a cytotoxic drug. Targets drug specifically to cancer cells. Example: Kadcyla (T-DM1) for HER2+ breast cancer. Enfortumab vedotin for bladder cancer. The "guided missile" approach — maximum tumour kill, minimal side effects.
🦇 m102.4 — Nipah Virus Monoclonal Antibody UPSC PYQ 2025
What is m102.4? A fully human monoclonal antibody that neutralises both Nipah virus and Hendra virus — by binding to the receptor-binding domain of the viral glycoprotein G (surface protein), preventing the virus from attaching to human cells.
Status: Passed Phase I clinical trials (safety in healthy volunteers). Administered to 14 individuals globally on a compassionate-use basis — none of the 14 died from the virus. Available in limited stock (Australia is a primary source).
Compassionate Use: Allowed for unauthorised medicines when: (1) no other approved treatment exists AND (2) patient cannot enter clinical trials. India used this during Nipah outbreaks in Kerala (2018, 2021, 2023).
India angle: During the 2023 Nipah outbreak in Kerala, India reached out to Australia to restock m102.4 doses. The mortality rate of Nipah is 40–70% — far higher than COVID-19 (2–3%). Building domestic mAb manufacturing capacity is a strategic priority.
Status: Passed Phase I clinical trials (safety in healthy volunteers). Administered to 14 individuals globally on a compassionate-use basis — none of the 14 died from the virus. Available in limited stock (Australia is a primary source).
Compassionate Use: Allowed for unauthorised medicines when: (1) no other approved treatment exists AND (2) patient cannot enter clinical trials. India used this during Nipah outbreaks in Kerala (2018, 2021, 2023).
India angle: During the 2023 Nipah outbreak in Kerala, India reached out to Australia to restock m102.4 doses. The mortality rate of Nipah is 40–70% — far higher than COVID-19 (2–3%). Building domestic mAb manufacturing capacity is a strategic priority.
📊 Nipah Virus Key Facts (UPSC)
🦇 Zoonotic — fruit bats (Pteropus) are natural reservoir
☠ Mortality: 40–70% (classified as BSL-4 pathogen)
🧠 Causes encephalitis (brain inflammation) + respiratory illness
📍 India outbreaks: Kerala 2018, 2021, 2023, 2024, 2025
💉 No approved vaccine yet — m102.4 is only available treatment (compassionate)
🌍 WHO Priority pathogen — potential for pandemic
☠ Mortality: 40–70% (classified as BSL-4 pathogen)
🧠 Causes encephalitis (brain inflammation) + respiratory illness
📍 India outbreaks: Kerala 2018, 2021, 2023, 2024, 2025
💉 No approved vaccine yet — m102.4 is only available treatment (compassionate)
🌍 WHO Priority pathogen — potential for pandemic
🧪 ELISA — How mAbs Enable Diagnosis
🇮🇳
India's mAb Story — Biosimilars, NexCAR19 & Self-Reliance
Biocon · CAR-T · ESTIC 2025 · Nipah · Policy
🌍 India's Position in the mAb World
India is the world's leading manufacturer of biosimilar monoclonal antibodies for emerging markets. India produces mAb biosimilars at 30–50% of Western manufacturing costs — making cancer and autoimmune treatments accessible to millions. Key players: Biocon Biologics, Dr. Reddy's Laboratories, Cipla, Intas Pharmaceuticals.
🎗
Canmab — India's Herceptin Biosimilar
Biocon Biologics developed Canmab (trastuzumab biosimilar) — India's first monoclonal antibody biosimilar for breast cancer. Price: ~₹25,000 vs ₹75,000+ for originator Herceptin. Approved by CDSCO 2013. Also got FDA approval as Ogivri (2017) — first FDA-approved trastuzumab biosimilar.
💉
Casirivimab + Imdevimab — COVID mAbs in India
Roche's REGEN-COV (casirivimab + imdevimab combination) was granted Emergency Use Authorisation in India (2021) for mild-to-moderate COVID-19 in high-risk patients. BCCI president Sourav Ganguly received monoclonal antibody treatment after COVID-19 infection — brought this topic to public attention.
🚀 NexCAR19 — India's CAR-T Breakthrough (UPSC Current Affairs 2023–2025)
What is it? NexCAR19 is India's first indigenous CAR-T cell therapy — approved by CDSCO in October 2023. It is also the world's first humanised CAR-T therapy.
What is CAR-T? A patient's T-cells (immune cells) are extracted → genetically engineered in lab to express a Chimeric Antigen Receptor (CAR) targeting CD19 protein on B-cell cancers → reinfused → "living drug" that hunts and kills cancer cells.
Used for: Relapsed/refractory B-cell Non-Hodgkin's Lymphoma & B-cell Acute Lymphoblastic Leukaemia — cancers where chemo failed.
ESTIC 2025: PM Modi unveiled NexCAR19 at the Emerging Science, Technology & Innovation Conclave (ESTIC) 2025 as one of three flagship national innovations.
What is CAR-T? A patient's T-cells (immune cells) are extracted → genetically engineered in lab to express a Chimeric Antigen Receptor (CAR) targeting CD19 protein on B-cell cancers → reinfused → "living drug" that hunts and kills cancer cells.
Used for: Relapsed/refractory B-cell Non-Hodgkin's Lymphoma & B-cell Acute Lymphoblastic Leukaemia — cancers where chemo failed.
ESTIC 2025: PM Modi unveiled NexCAR19 at the Emerging Science, Technology & Innovation Conclave (ESTIC) 2025 as one of three flagship national innovations.
Developer: ImmunoACT (IIT Bombay spin-off) + Tata Memorial Hospital + supported by DBT & BIRAC
Cost: ~$50,000 (₹42 lakh) vs $500,000 in USA — 90% cheaper
Availability: 30+ hospitals across 10+ cities in India (as of 2024)
Clinical Trial: 64 patients — 87.5% objective response rate in Phase I
Cost: ~$50,000 (₹42 lakh) vs $500,000 in USA — 90% cheaper
Availability: 30+ hospitals across 10+ cities in India (as of 2024)
Clinical Trial: 64 patients — 87.5% objective response rate in Phase I
Link to mAbs: CAR-T is related to mAbs — the CAR receptor on T-cells is derived from the variable region of a monoclonal antibody. The CD19-targeting CAR is essentially a mAb fragment fused to a T-cell signalling domain — combining immunotherapy & genetic engineering.
| India Development | Drug/Product | Significance | Year |
|---|---|---|---|
| Biocon Biologics | Canmab (trastuzumab biosimilar) | India's first mAb biosimilar for cancer; FDA approved as Ogivri | 2013 (India) / 2017 (FDA) |
| Dr. Reddy's Laboratories | Reditux (rituximab biosimilar) | World's first rituximab biosimilar | 2007 |
| ImmunoACT (IIT Bombay) | NexCAR19 (CAR-T) | India's first & world's first humanised CAR-T; CDSCO approved | October 2023 |
| Immuneel Therapeutics | Qartemi (CAR-T) | India's second approved CAR-T therapy for B-NHL | 2024 |
| Roche India / CDSCO | Casirivimab + Imdevimab | Emergency Use Authorisation for COVID-19 in India | 2021 |
| Australia → India (m102.4) | m102.4 antibody | Procured by India for Nipah outbreaks in Kerala on compassionate use basis | 2023 onwards |
⚠ Strategic Gap — Domestic Nipah mAb Capacity
India has faced repeated Nipah outbreaks (Kerala: 2018, 2021, 2023, 2024, 2025) — all managed largely through containment, not treatment, because India has no domestic manufacturing capacity for m102.4. Every time, India depends on Australia for limited doses. Given that Nipah has WHO pandemic potential (40–70% mortality, human-to-human spread), India's National Biopharma Mission must prioritise developing indigenous Nipah mAbs. This is a major UPSC Mains policy question: science + public health + strategic self-reliance.
⚠
Challenges & Limitations of Monoclonal Antibodies
Cost · Resistance · Cold Chain · Access
💰
Prohibitive Cost
mAbs are among the most expensive medicines. Pembrolizumab (Keytruda): ~₹3–4 lakh/dose. Adalimumab (Humira): ₹50,000–1 lakh/month. Manufacturing in mammalian cell culture (CHO cells) is enormously complex. Even Indian biosimilars cost ₹15,000–50,000 per dose — unaffordable for most.
🧊
Cold Chain Requirement
All mAbs require strict refrigeration (2–8°C). Unlike tablets, they cannot be stored at room temperature. India's cold chain infrastructure is weak in rural areas — a major barrier to distribution. A single temperature excursion can destroy an entire batch.
🔄
Antigen Escape / Resistance
Cancer cells can mutate the target antigen → mAb no longer recognises them → treatment failure. Viruses (e.g. SARS-CoV-2 variants) can mutate their surface proteins → COVID mAbs lost efficacy against Omicron. This requires constant development of new mAbs.
🛡
Immunogenicity
Early mouse-derived mAbs triggered immune reactions (HAMA — Human Anti-Mouse Antibody response). Solved by humanisation (-zumab) and fully human mAbs (-umab), but immunogenicity risk still exists for some patients, causing allergic reactions or loss of efficacy.
💉
Injection Only (No Oral Route)
mAbs are large protein molecules — destroyed by stomach acid and enzymes if swallowed. Must be given by IV infusion or subcutaneous injection. This requires clinical settings, trained staff, and adds cost. Oral mAb formulations are under research.
🧬
Manufacturing Complexity
Produced in mammalian cells (CHO cells) under extremely precise conditions. Even small changes in temperature, pH, or nutrients alter the drug product. This is why mAb biosimilars are "highly similar" not identical — batch-to-batch variation is inherent. Requires sophisticated bioprocessing infrastructure.
📜
PYQs & Practice MCQs
UPSC Prelims 2025 PYQ + Practice MCQs
📜 UPSC Prelims 2025 — GS Paper I (Q. 48) Direct Hit
PYQ 2025
Q. With reference to monoclonal antibodies, often mentioned in news, consider the following statements:
- They are man-made proteins.
- They stimulate immunological function due to their ability to bind to specific antigens.
- They are used in treating viral infections like that of Nipah virus.
- a) 1 only
- b) 1 and 2 only
- c) 2 and 3 only
- d) 1, 2 and 3 ✓
Statement 1 CORRECT: Monoclonal antibodies are laboratory-engineered (man-made) proteins — specifically immunoglobulins — produced by cloning a single B-cell type.
Statement 2 CORRECT: By binding to specific antigens (e.g., cancer surface proteins, viral proteins), mAbs stimulate immune effector mechanisms — including ADCC (Natural Killer cells attack), complement activation, and checkpoint unblocking — which enhance immunological function.
Statement 3 CORRECT: m102.4 is a fully human monoclonal antibody used against Nipah and Hendra virus on compassionate-use basis in India (Kerala outbreaks). Monoclonal antibodies have also been used against Ebola (Inmazeb — FDA approved), COVID-19, and are under investigation for HIV (bNAbs). All three statements are correct.
Statement 2 CORRECT: By binding to specific antigens (e.g., cancer surface proteins, viral proteins), mAbs stimulate immune effector mechanisms — including ADCC (Natural Killer cells attack), complement activation, and checkpoint unblocking — which enhance immunological function.
Statement 3 CORRECT: m102.4 is a fully human monoclonal antibody used against Nipah and Hendra virus on compassionate-use basis in India (Kerala outbreaks). Monoclonal antibodies have also been used against Ebola (Inmazeb — FDA approved), COVID-19, and are under investigation for HIV (bNAbs). All three statements are correct.
📜 UPSC Mains 2022 — GS Paper III (Based Pattern · 10 marks)
Mains Pattern
Q. "Monoclonal antibodies represent a paradigm shift in the treatment of cancer and infectious diseases." Discuss with suitable examples, highlighting India's contributions and challenges in this field. (10 marks)
Model Answer Framework:
Model Answer Framework:
- Introduction: Define mAbs. Mention Nobel 1984 (Köhler, Milstein, Jerne). Global mAb market ~$250 billion (2024). Paradigm shift from broad chemo to precision therapy.
- How they work: Direct blocking · ADCC/immune flagging · ADCs (Trojan horse) · Checkpoint inhibitors (PD-1/PD-L1)
- Cancer applications: Herceptin (HER2+ breast cancer) · Keytruda (PD-1, multiple cancers) · Avastin (anti-VEGF, colorectal) · Rituximab (CD20, lymphoma)
- Infectious disease: COVID-19 (casirivimab+imdevimab) · Nipah (m102.4, compassionate use) · Ebola (Inmazeb)
- India contribution: Canmab/Ogivri (Biocon — first India mAb biosimilar) · Reditux (Dr. Reddy's — first rituximab biosimilar globally) · NexCAR19 (CAR-T, CDSCO Oct 2023, world's first humanised) · ESTIC 2025 · m102.4 procurement for Kerala Nipah
- Challenges: Cost (₹3–4 lakh/dose for Keytruda) · Cold chain gaps · Antigen escape/variant resistance · Oral administration not possible · Immunogenicity · No domestic Nipah mAb capacity
- Policy recommendations: National Biopharma Mission · BIRAC funding · Jan Aushadhi for biosimilar mAbs · Mandatory HER2 testing before treatment · Domestic Nipah mAb development
🧪 Practice MCQs — Monoclonal Antibodies (Click to attempt)
Q1. The "Hybridoma technique" used in the production of monoclonal antibodies involves fusing which two types of cells?
- (a) T-cell and stem cell
- (b) Antibody-producing B-cell and immortal myeloma (cancer) cell
- (c) Red blood cell and dendritic cell
- (d) NK cell and plasma cell
The hybridoma technique (developed by Köhler & Milstein, Nobel 1984) fuses a short-lived antibody-producing B-cell (plasma cell) with an immortal myeloma (cancer) cell. The result is a "hybridoma" — a cell that is both immortal (can grow indefinitely in culture) AND produces one specific antibody. This solved the key problem: individual B-cells die quickly and cannot be maintained in large quantities, while myeloma cells are immortal but don't produce useful antibodies. The fusion gives the best of both.
Q2. Consider the following suffix conventions for monoclonal antibody names:
1. -umab → Fully human monoclonal antibody
2. -zumab → Humanised (mouse antibody modified to be mostly human)
3. -ximab → Chimeric (part human, part mouse)
4. -omab → Mouse (murine) origin
Which of the above is/are correctly matched?
1. -umab → Fully human monoclonal antibody
2. -zumab → Humanised (mouse antibody modified to be mostly human)
3. -ximab → Chimeric (part human, part mouse)
4. -omab → Mouse (murine) origin
Which of the above is/are correctly matched?
- (a) 1 and 2 only
- (b) 1, 2 and 3 only
- (c) 2, 3 and 4 only
- (d) 1, 2, 3 and 4
All four suffix conventions are correct per WHO INN (International Nonproprietary Name) nomenclature rules. -umab: fully human (Adalimumab/Humira). -zumab: humanised — mouse antibody with human constant regions substituted (Pembrolizumab/Keytruda, Trastuzumab/Herceptin). -ximab: chimeric — ~65% human, ~35% mouse (Rituximab/Rituxan, Cetuximab/Erbitux). -omab: purely murine/mouse — rarely used clinically due to high immunogenicity (HAMA response). This naming system is directly UPSC-tested and helps identify the antibody's origin and likely immunogenicity profile.
Q3. Which of the following correctly describes the mechanism of "Immune Checkpoint Inhibitors" — a class of monoclonal antibodies?
- (a) They directly kill cancer cells by delivering attached toxins
- (b) They stimulate the production of new T-cells in the bone marrow
- (c) They block proteins like PD-1 or PD-L1 that cancer cells use to suppress T-cells, allowing T-cells to recognise and destroy cancer
- (d) They bind to cancer cell surface antigens and flag them for destruction by NK cells
Immune Checkpoint Inhibitors (ICIs) like Pembrolizumab (Keytruda) and Nivolumab (Opdivo) block the PD-1/PD-L1 pathway. Normally, cancer cells express PD-L1 on their surface, which binds PD-1 on T-cells → T-cells are suppressed (cancer "hides"). mAb blocks this interaction → T-cells are "unleashed" → they can now recognise and kill cancer cells. Option (a) describes ADCs. Option (d) describes ADCC. Note: the Nobel Prize in Physiology or Medicine 2018 was awarded to James Allison (CTLA-4) and Tasuku Honjo (PD-1) for discovering checkpoint inhibition — a potential UPSC angle.
Q4. With reference to NexCAR19, consider the following statements:
1. It was approved by CDSCO in October 2023 as India's first CAR-T cell therapy.
2. It was developed by ImmunoACT, an IIT Bombay spin-off, with support from DBT and BIRAC.
3. It targets the CD19 protein on B-cell cancers.
4. It is priced approximately the same as CAR-T therapies in the USA.
Which are correct?
1. It was approved by CDSCO in October 2023 as India's first CAR-T cell therapy.
2. It was developed by ImmunoACT, an IIT Bombay spin-off, with support from DBT and BIRAC.
3. It targets the CD19 protein on B-cell cancers.
4. It is priced approximately the same as CAR-T therapies in the USA.
Which are correct?
- (a) 1 and 2 only
- (b) 1, 2 and 4 only
- (c) 1, 2 and 3 only
- (d) 1, 2, 3 and 4
Statements 1, 2, and 3 are correct. Statement 4 is WRONG — NexCAR19 costs ~$50,000 (≈₹42 lakh) in India vs ~$500,000 in the USA, making it approximately 90% cheaper than US CAR-T therapies. This affordability was specifically highlighted by PM Modi at ESTIC 2025 as India's achievement in making advanced therapies accessible. NexCAR19 is also the world's first humanised CAR-T therapy (the CAR receptor is humanised like a -zumab type antibody), reducing immunogenicity compared to standard CAR-T.
Q5. m102.4, the monoclonal antibody used in treating Nipah virus infection, is described as being used on a "compassionate use" basis. What does this mean?
- (a) The drug is freely available without prescription because it is approved globally
- (b) The drug is allowed for use in patients for whom no other approved treatment exists and who cannot enter clinical trials, even though the drug itself is not fully approved
- (c) The drug is manufactured compassionately without profit, making it free for patients
- (d) The drug is used only when patients give emotional consent to bear all risks
"Compassionate use" (also called expanded access) allows an unauthorised/unapproved medicine to be used under strict conditions when: (1) the patient has a serious or life-threatening condition, (2) no other satisfactory approved treatment is available, and (3) the patient cannot participate in clinical trials. m102.4 has only passed Phase I trials — it is NOT fully approved. During Nipah outbreaks in Kerala, where mortality is 40–70% and no approved treatment exists, CDSCO permits its use under compassionate provisions. India procured limited doses from Australia for this purpose. The 14 individuals globally who received m102.4 all survived — though this is still insufficient for regulatory approval (small numbers, no controlled trial).
Q6. ELISA (Enzyme-Linked Immunosorbent Assay), widely used in medical diagnostics, fundamentally relies on:
- (a) Polymerase chain reaction (PCR) amplification of DNA
- (b) Gel electrophoresis separation of proteins by molecular weight
- (c) The highly specific binding of monoclonal antibodies to their target antigens, detected through an enzyme-linked colour reaction
- (d) CRISPR-Cas9 gene editing to identify disease mutations
ELISA uses the specificity of monoclonal antibodies to detect and quantify antigens in a sample. A capture antibody (mAb) is coated on a plate → patient sample added → target antigen binds → a second detection antibody (also mAb, linked to an enzyme) binds to the antigen → substrate added → enzyme converts substrate to coloured product → colour intensity indicates antigen concentration. ELISA is used for: HIV diagnosis, Hepatitis B/C detection, COVID-19 antigen/antibody tests, pregnancy (hCG), food allergen detection, drug levels in blood. It is the basis for home pregnancy tests and COVID-19 rapid antigen kits — both use mAb-based lateral flow technology.
⚡ Quick Revision — Monoclonal Antibodies Summary
| Topic | Key Facts to Remember |
|---|---|
| Definition | Lab-made protein targeting ONE specific antigen. Identical clones from one B-cell. "Mono" = one, "Clonal" = identical copies. mAb / MAb / MoAb. |
| Nobel Prize | 1984 — Niels K. Jerne + Georges Köhler + César Milstein. For hybridoma technique (Köhler & Milstein published 1975). One of the most cited science papers. |
| Structure | Y-shaped immunoglobulin. Fab arms = antigen-binding (variable region). Fc stem = immune effector functions. Variable region engineered to target ONE specific antigen. |
| 4 Mechanisms | (1) Direct blocking/neutralisation (2) ADCC — flag cell for NK cell attack (3) ADC — drug delivery Trojan horse (4) Checkpoint inhibition — unblock T-cells (PD-1/PD-L1) |
| Naming Suffixes | -umab = fully human · -zumab = humanised · -ximab = chimeric · -omab = murine (mouse) |
| Production | Hybridoma method: immunise mouse → harvest B-cells → fuse with myeloma → select hybridoma → mass produce in CHO cells. UPSC: Köhler & Milstein → Nobel 1984. |
| Key Examples | Trastuzumab/Herceptin (HER2+ breast cancer) · Rituximab (lymphoma) · Adalimumab/Humira (RA) · Pembrolizumab/Keytruda (PD-1, cancer) · Casirivimab+Imdevimab (COVID) · m102.4 (Nipah) |
| m102.4 / Nipah | Fully human mAb. Neutralises Nipah+Hendra by binding glycoprotein G. Phase I trials complete. 14 patients globally (compassionate use). India imports from Australia. UPSC Prelims 2025 tested. |
| NexCAR19 India | CAR-T therapy. India's first (CDSCO Oct 2023). World's first humanised CAR-T. ImmunoACT (IIT Bombay) + Tata Memorial. DBT+BIRAC support. Cost ~₹42 lakh (vs ₹4 crore abroad). PM Modi unveiled at ESTIC 2025. |
| India mAb Biosimilars | Canmab (Biocon — Herceptin biosimilar, 2013) · Reditux (Dr. Reddy's — world's first rituximab biosimilar, 2007) · Ogivri (Biocon — FDA approved trastuzumab, 2017) |
| ELISA Diagnostics | mAb-based colour assay. Detects specific antigen in sample. Used for HIV, Hepatitis, COVID-19 antigen, pregnancy (hCG), food safety, drug monitoring. |
| Challenges | Very expensive · Cold chain 2–8°C · Injection only (not oral) · Antigen escape (variant resistance) · Immunogenicity · Complex manufacturing |
🚨 5 UPSC Traps — Monoclonal Antibodies:
Trap 1 — "mAbs stimulate the immune system to produce more antibodies" → WRONG! mAbs are laboratory-produced proteins themselves — they DO NOT stimulate the body to produce more antibodies. They function directly as antibodies. Vaccines stimulate the immune system to produce antibodies. mAbs are the antibodies themselves, administered externally. UPSC 2025 tested this nuance — Statement II said "they stimulate immunological function due to binding to antigens" which is correct (they trigger ADCC, complement, etc.) but they don't stimulate antibody production.
Trap 2 — "m102.4 is approved for Nipah treatment in India" → WRONG! m102.4 is NOT approved — it is used only on compassionate use basis. It has only passed Phase I trials (safety testing). Full approval requires Phase II (efficacy) and Phase III (large-scale) trials — which have not been completed because Nipah outbreaks are rare and small. "Compassionate use" ≠ "approved medicine".
Trap 3 — "NexCAR19 is a monoclonal antibody" → PARTIALLY MISLEADING! NexCAR19 is a CAR-T cell therapy — it is a living cell therapy, not a protein drug. However, the CAR (Chimeric Antigen Receptor) engineered into the T-cells is derived from the variable region of a monoclonal antibody (anti-CD19). So it uses mAb technology but is administered as engineered T-cells, not as a protein injection. The distinction matters for UPSC.
Trap 4 — "Immune checkpoint inhibitors kill cancer cells directly" → WRONG! ICIs (Pembrolizumab, Nivolumab) do NOT directly kill cancer cells. They block PD-1/PD-L1 proteins → remove the "brake" on T-cells → T-cells then kill cancer cells. The mAb's role is to unlock the immune system, not to destroy cancer itself. This makes them fundamentally different from ADCs (which do deliver toxins directly) or ADCC (which flags cells for NK attack).
Trap 5 — "Hybridoma technique uses human cells" → WRONG! The classic hybridoma technique uses mouse (murine) B-cells fused with mouse myeloma cells — the resulting mAbs are mouse antibodies (-omab), which caused HAMA reactions in patients. To solve this, scientists progressively humanised mAbs: chimeric (-ximab) → humanised (-zumab) → fully human (-umab). Fully human mAbs now use phage display or transgenic mice with human antibody genes. The Nobel 1984 was specifically for this original mouse-based hybridoma technique.
Trap 1 — "mAbs stimulate the immune system to produce more antibodies" → WRONG! mAbs are laboratory-produced proteins themselves — they DO NOT stimulate the body to produce more antibodies. They function directly as antibodies. Vaccines stimulate the immune system to produce antibodies. mAbs are the antibodies themselves, administered externally. UPSC 2025 tested this nuance — Statement II said "they stimulate immunological function due to binding to antigens" which is correct (they trigger ADCC, complement, etc.) but they don't stimulate antibody production.
Trap 2 — "m102.4 is approved for Nipah treatment in India" → WRONG! m102.4 is NOT approved — it is used only on compassionate use basis. It has only passed Phase I trials (safety testing). Full approval requires Phase II (efficacy) and Phase III (large-scale) trials — which have not been completed because Nipah outbreaks are rare and small. "Compassionate use" ≠ "approved medicine".
Trap 3 — "NexCAR19 is a monoclonal antibody" → PARTIALLY MISLEADING! NexCAR19 is a CAR-T cell therapy — it is a living cell therapy, not a protein drug. However, the CAR (Chimeric Antigen Receptor) engineered into the T-cells is derived from the variable region of a monoclonal antibody (anti-CD19). So it uses mAb technology but is administered as engineered T-cells, not as a protein injection. The distinction matters for UPSC.
Trap 4 — "Immune checkpoint inhibitors kill cancer cells directly" → WRONG! ICIs (Pembrolizumab, Nivolumab) do NOT directly kill cancer cells. They block PD-1/PD-L1 proteins → remove the "brake" on T-cells → T-cells then kill cancer cells. The mAb's role is to unlock the immune system, not to destroy cancer itself. This makes them fundamentally different from ADCs (which do deliver toxins directly) or ADCC (which flags cells for NK attack).
Trap 5 — "Hybridoma technique uses human cells" → WRONG! The classic hybridoma technique uses mouse (murine) B-cells fused with mouse myeloma cells — the resulting mAbs are mouse antibodies (-omab), which caused HAMA reactions in patients. To solve this, scientists progressively humanised mAbs: chimeric (-ximab) → humanised (-zumab) → fully human (-umab). Fully human mAbs now use phage display or transgenic mice with human antibody genes. The Nobel 1984 was specifically for this original mouse-based hybridoma technique.
